Antiangiogenic tyrosine kinase inhibitors (AA‐TKIs), such as regorafenib and axitinib, inhibit tumour angiogenesis by suppressing the vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) signalling pathway (Grothey et al., 2013; Sharma et al., 2010). Here, KDR is linked to neoplasm.